Seattle Genetics, Inc . SGEN announced that it has actually initiated a phase III trial, CASCADE, when it come to vadastuximab talirine (SGN-CD33A).
The randomized, double-blind, placebo-controlled trial will certainly evaluate if vadastuximab talirine, in combination along with Vidaza or Dacogen, can easily expand total survival compared to Vidaza or Dacogen alone in older patients along with newly diagnosed acute myeloid leukemia (AML).
We note that Vidaza and Dacogen are hypomethylating agents (HMAs) that are often utilized for the procedure of older AML patients.
According to the American Cancer Society, AML will certainly influence 20,000 people in the U.S. in 2016, and bring about 10,500 deaths. Hence, there is substantial reason for therapies in this area.
The trial will certainly enroll 500 patients globally that will certainly be randomized when it come to a 1:1 ratio to be treated along with an HMA plus 33A or an HMA plus placebo.
Interim outcomes from the ongoing phase I study, analyzing 33A in combination along with HMAs in frontline AML and as monotherapy in primarily relapsed AML, were presented in 2015. Data from the phase I 33A combination trial showed that 15 from 23 (65%) evaluable patients obtained finish remission and finish remission along with incomplete hematologic recovery (CR/Cri). Updated data from the ongoing phase I study when it come to 33A in combination along with HMAs will certainly be presented in an oral presentation at the 2016 European Hematology Association Congress scheduled following month.
Meanwhile, Seattle Genetics is analyzing 33A across multiple lines of treatment in patients along with AML and myelodysplastic syndromes (MDS) in numerous trials.
We note that Adcetris is the just marketed product in Seattle Genetics’ portfolio, which has actually gained the business highly dependent when it come to the drug for growth. As a result, the improvement of pipeline candidates is crucial for the business to minimize its dependence when it come to Adectris. Successful improvement and commercialization of vadastuximab talirine will certainly increase Seattle Genetics’ leading line significantly.
Seattle Genetics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector consist of Abbott Laboratories ABT , Johnson & Johnson JNJ and Sanofi SNY . every one of 3 stocks carry a Zacks Rank #2 (Buy).
Want the most recent help from Zacks Investment Research? Today, you can easily download 7 Ideal Stocks for the following 30 Days. Click to grab this free report >>
Want the most recent help from Zacks Investment Research? Today, you can easily download 7 Ideal Stocks for the following 30 Days. Click to grab this free report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
SEATTLE GENETIC (SGEN): Free Stock Analysis Report
To read this write-up when it come to Zacks.com click here.
The sights and opinions expressed herein are the sights and opinions of the author and do not essentially reflect those of Nasdaq, Inc.
